Sign in
CompletedPhase 2

Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder

Key facts

Who runs it
Universitaetsmedizin Goettingen
Where
Germany1 site in 1 countryChoose a country to see its sites
Status
Completed
Phase
Phase 2
People taking part
50 people enrolled
Started
20 Mar 2023
Ended
4 Mar 2026
Type of study
Interventional
Record updated
23 July 2024

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients with BED according to DSM-5
  • Male or female patients aged between 18 and 40 (the upper age limit was chosen to minimise potential confounding effects by hormonal changes related to menopause)
  • Written informed consent obtained according to international guidelines and local laws
  • Ability to understand the nature of the trial and the trial related procedures and to comply with them

Who cannot take part

  • current or planned use of psychotropic medication (during the period of the study)
  • current diagnosis of a psychotic, bipolar, or substance use disorder
  • severe somatic illness (e.g. cancer, cardiovascular disease, instable diabetes mellitus; blood pressure ≥ 160/100 mmHg at rest and/or current treatment of hypertensive crisis within last 6 months)
  • known hypersensitivity to hydrocortisone
  • known glucose-galactose malabsorption
  • systemic (i.v. or oral) glucocorticoid treatment within the last 3 months
  • known pheochromocytoma
  • Simultaneous participation in another interventional trial
  • Pregnant or breastfeeding females
  • current or planned psychotherapy (during the period of the study)
  • known hereditary galactose intolerance
  • known lactase deficiency

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The central research question of this project is whether a combination of (food) exposure with response prevention (ERP) and cortisol is superior to ERP under placebo in terms of the reduction of craving for food in Binge Eating Disorder (BED).

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
23 July 2024